dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Napolitano, Stefania |
dc.contributor.author | Matrone, Nunzia |
dc.contributor.author | Muddassir, A. L. |
dc.contributor.author | Martini, Giulia |
dc.contributor.author | Sorokin, A. |
dc.contributor.author | De Falco, Vincenzo |
dc.date.accessioned | 2021-04-20T09:42:10Z |
dc.date.available | 2021-04-20T09:42:10Z |
dc.date.issued | 2019-12-16 |
dc.identifier.citation | Napolitano S, Matrone N, Muddassir AL, Martini G, Sorokin A, De Falco V, et al. Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression. J Exp Clin Cancer Res. 2019 Dec 16;38(1):492. |
dc.identifier.issn | 1756-9966 |
dc.identifier.uri | https://hdl.handle.net/11351/5877 |
dc.description | Càncer colorectal; Resistència a inhibidors de MEK; Inhibidors de PD-L1 |
dc.description.sponsorship | This research has been supported by a grant from Associazione Italiana per la Ricerca sul Cancro (AIRC) to FC (AIRC IG 18972) and and Regione Campania Cancer Research Campaign I-CURE grant to FC. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Journal of Experimental & Clinical Cancer Research;38(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Recte - Càncer |
dc.subject | Còlon - Càncer |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /genetics |
dc.subject.mesh | Drug Resistance, Neoplasm |
dc.title | Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13046-019-1497-0 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /genética |
dc.subject.decs | resistencia a los antineoplásicos |
dc.relation.publishversion | https://jeccr.biomedcentral.com/articles/10.1186/s13046-019-1497-0 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Napolitano S] Medical Oncology Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicin0065, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. [Matrone N] Medical Oncology Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy. Medical University of Vienna, Institute for Cancer Research, Borschkegasse 8A, 1090 Wien, Austria. [Muddassir AL, Sorokin A] Department of Gastrointestinal Medical Oncology, Division of Cancer Medicin0065, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA. [Martini G] Medical Oncology Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy. Gastrointestinal and neuroendocrine tumor group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [De Falco V] Medical Oncology Department of Precision Medicine, University of Campania “Luigi Vanvitelli”, 80100 Naples, Italy |
dc.identifier.pmid | 31842958 |
dc.identifier.wos | 000510641700001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |